These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34366292)

  • 41. [A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial].
    Blanchard P; Foulon S; Louvel G; Habibian M; Fizazi K
    Cancer Radiother; 2017 Oct; 21(6-7):491-494. PubMed ID: 28869198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
    Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
    Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.
    Fanetti G; Marvaso G; Ciardo D; Rese A; Ricotti R; Rondi E; Comi S; Cattani F; Zerini D; Fodor C; de Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 Apr; 35(5):75. PubMed ID: 29671075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. STAT RT: a prospective pilot clinical trial of Scan-Plan-QA-Treat stereotactic body radiation therapy for painful osseous metastases.
    Wilson DD; Alonso CE; Sim AJ; Peck T; Handsfield LL; Chen Q; Blackhall L; Showalter TN; Reardon KA; Read PW
    Ann Palliat Med; 2019 Jul; 8(3):221-230. PubMed ID: 30691281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary cancer risk from modern external-beam radiotherapy of prostate cancer patients: Impact of fractionation and dose distribution.
    Sitathanee C; Tangboonduangjit P; Dhanachai M; Suntiwong S; Yongvithisatid P; Rutchantuk S; Changkaew P; Watjiranon R; Khachonkham S; Boonkitticharoen V
    J Radiat Res; 2021 Jul; 62(4):707-717. PubMed ID: 33993271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
    Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
    Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
    Ali A; Hoyle AP; Parker CC; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Attard G; Parmar MKB; Sydes MR; James ND; Clarke NW;
    Eur Urol Oncol; 2020 Aug; 3(4):412-419. PubMed ID: 32591246
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort.
    Pielkenrood BJ; van der Velden JM; van der Linden YM; Bartels MMT; Kasperts N; Verhoeff JJC; Eppinga WSC; Gal R; Verlaan JJ; Verkooijen HML
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):358-367. PubMed ID: 33333200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET).
    Mercier C; Dirix P; Ost P; Billiet C; Joye I; Vermeulen P; Lievens Y; Verellen D
    BMC Cancer; 2019 Sep; 19(1):876. PubMed ID: 31484505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy.
    Sprave T; Verma V; Förster R; Schlampp I; Bruckner T; Bostel T; Welte SE; Tonndorf-Martini E; Nicolay NH; Debus J; Rief H
    Radiother Oncol; 2018 Aug; 128(2):274-282. PubMed ID: 29843899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016-2018.
    Gillespie EF; Lapen K; Wang DG; Wijetunga N; Pastrana GL; Kollmeier MA; Yamada J; Schmitt AM; Higginson DS; Vaynrub M; Santos Martin E; Xu AJ; Tsai C; Yerramilli D; Cahlon O; Yang T
    Clin Transl Radiat Oncol; 2020 Nov; 25():75-80. PubMed ID: 33102818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors affecting the use of single-fraction radiotherapy for the palliation of bone metastases in Australia.
    Petrushevski AN; Gabriel GS; Hanna TP; Allen S; Allison RW; Barton MB
    Clin Oncol (R Coll Radiol); 2015 Apr; 27(4):205-12. PubMed ID: 25533480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
    Al-Hallaq HA; Chmura S; Salama JK; Winter KA; Robinson CG; Pisansky TM; Borges V; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Timmerman RD; White JR; Xiao Y; Matuszak MM
    Pract Radiat Oncol; 2016; 6(6):e291-e298. PubMed ID: 27345129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases.
    Seal B; Sullivan SD; Ramsey SD; Asche CV; Shermock K; Sarma S; Zagadailov EA; Farrelly E; Eaddy M
    Appl Health Econ Health Policy; 2014 Oct; 12(5):547-57. PubMed ID: 25005491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer.
    Robinson TJ; Dinan MA; Li Y; Lee WR; Reed SD
    J Palliat Med; 2015 Nov; 18(11):933-9. PubMed ID: 26241733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radiological changes on CT after stereotactic body radiation therapy to non-spine bone metastases: a descriptive series.
    Chiu N; Probyn L; Raman S; McDonald R; Poon I; Erler D; Brotherston D; Soliman H; Cheung P; Chung H; Chu W; Loblaw A; Thavarajah N; Lang C; Chin L; Chow E; Sahgal A
    Ann Palliat Med; 2016 Apr; 5(2):116-24. PubMed ID: 27121739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.